Agency Forms Undergoing Paperwork Reduction Act Review, 3305-3306 [E6-617]

Download as PDF Federal Register / Vol. 71, No. 13 / Friday, January 20, 2006 / Notices costs for all entities subject to the TSR is $5,613,200.5 Finally, staff believes that the estimated 4,000 inbound telemarketing entities choosing to comply with the Rule through written disclosures incur no additional capital or operating expenses as a result of the Rule’s requirements because they are likely to provide written information to prospective customers in the ordinary course of business. Adding the required disclosures to that written information likely requires no supplemental nonlabor expenditures. John D. Graubert, Acting General Counsel. [FR Doc. E6–627 Filed 1–19–06; 8:45 am] BILLING CODE 6750–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Vaccine Advisory Committee Department of Health and Human Services, Office of the Secretary, Office of Public Health and Science. ACTION: Notice. wwhite on PROD1PC65 with NOTICES AGENCY: Authority: 42 U.S.C. 300aa–5, Section 2105 of the Public Health Service (PHS) Act, as amended. The Committee is governed by the provisions of Public Law 92–463, as amended (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of advisory committees. SUMMARY: The National Vaccine Program Office (NVPO), a program office within the Office of Public Health and Science, U.S. Department of Health and Human Services (HHS), is soliciting nominations of qualified candidates to be considered for appointment as voting representative members to the National Vaccine Advisory Committee (NVAC). The activities of this Committee are governed by the Federal Advisory Committee Act (FACA). Consistent with the National Vaccine Plan, the Committee advises and makes recommendations to the Assistant Secretary for Health in his/her capacity as the Director of the National Vaccine Program, on matters related to the Program’s responsibilities. Specifically, the Committee studies and recommends ways to encourage the availability of an adequate supply of safe and effective vaccination products in the United States; recommends research priorities and other measures to enhance the 5 Staff believes that remaining non-labor costs would largely be incurred by affected entities, regardless, in the ordinary course of business and/ or marginally be above such costs. VerDate Aug<31>2005 16:16 Jan 19, 2006 Jkt 208001 safety and efficacy of vaccines. The Committee also advises the Assistant Secretary for Health in the implementation of Sections 2102 and 2103 of the PHS Act; and identifies annually the most important areas of government and non-government cooperation that should be considered in implementing Sections 2102 and 2103 of the PHS Act. DATES: Nominations for membership on the Committee must be received no later than 5 p.m. e.s.t. on March 3, 2006, at the address below. ADDRESSES: All nomination should be mailed or delivered to: Bruce G. Gellin, M.D., M.P.H., Executive Secretary, National Vaccine Advisory Committee, Office of Public Health and Science, Department of Health and Human Services, 200 Independence Avenue, SW., Room 443–H, Hubert H. Humphrey Building; Washington, DC 20201. FOR FURTHER INFORMATION CONTACT: Ms. Emma English, Program Analyst, National Vaccine Program Office, Department of Health and Human Services, 200 Independence Avenue, SW., Room 443–H, Hubert H. Humphrey Building, Washington, DC 20201; (202) 690–5566; nvac@osophs.dhhs.gov. A copy of the Committee charter and list of the current membership can be obtained by contacting Ms. English or by accessing the NVAC Web site at: https://www.hhs.gov/nvpo/nvac. SUPPLEMENTARY INFORMATION: Committee Function: Qualifications and Information Required: As part of an ongoing effort to enhance deliberations and discussions with the public on vaccine and immunization policy, nominations are being sought for interested individuals to serve on the Committee. The individual selected for appointment to the Committee will serve as a voting representative member. Voting representative members are official representatives of the vaccine manufacturing industry who are engaged in vaccine research or the manufacture of vaccines. Individuals selected for appointment to the Committee can be invited to serve terms with periods of up to four years. Nominations should be typewritten. The following information should be included in the package of material submitted for each individual being nominated for consideration: (1) A letter of nomination that clearly states the name and affiliation of the nominee, the basis for the nomination (i.e., specific attributes which qualify the nominee for service in this capacity), and a statement that the nominee is willing to serve as a member of the Committee; (2) the nominator’s name, address and daytime PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 3305 telephone number, and the home and/ or work address, telephone number, and e-mail address of the individual being nominated; and (3) a current copy of the nominee’s curriculum vitae. Applications cannot be submitted by facsimile. The names of Federal employees should not be nominated for consideration of appointment to this Committee. The Department makes every effort to ensure that the membership of HHS Federal advisory committees is fairly balanced in terms of points of view represented and the committee’s function. Every effort is made that a broad representation of geographic areas, gender, ethnic and minority groups, and the disabled are given consideration for membership on HHS Federal advisory committees. Appointment to this committee shall be made without discrimination on the basis of age, race, ethnicity, gender, sexual orientation, disability, and cultural, religious, or socioeconomic status. Dated: January 13, 2006. Bruce Gellin, Director, National Vaccine Program Office. [FR Doc. E6–595 Filed 1–19–06; 8:45 am] BILLING CODE 4510–44–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30Day–06–05AV] Agency Forms Undergoing Paperwork Reduction Act Review The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 639–4766 or send an email to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of Management and Budget, Washington, DC or by fax to (202) 395–6974. Written comments should be received within 30 days of this notice. Proposed Project Hemophilia Treatment Center Laboratory Survey—New—National Center on Birth Defects and Developmental Disabilities (NCBDDD), Centers for Disease Control and Prevention (CDC). E:\FR\FM\20JAN1.SGM 20JAN1 3306 Federal Register / Vol. 71, No. 13 / Friday, January 20, 2006 / Notices Background and Brief Description Up to 2 million women in the United States may have an inherited bleeding disorder and not know it. Many women learn to live with the problems their bleeding causes, such as heavy periods, and do not realize that they may have a bleeding disorder. Other women may have more serious bleeding problems such as hemorrhages after childbirth or surgery, and some have hysterectomies to end their heavy periods. With proper diagnosis, women with bleeding disorders could avoid these complications and surgeries. Management of bleeding in these women can decrease heavy periods and can improve quality of life. The most common bleeding disorder is called Von Willebrand disease (VWD). VWD is caused by a deficiency or defect in the body’s ability to make a protein, Von Willebrand factor, which helps blood clot. The symptoms of VWD can range in severity; however, 90 percent of people who have this disease have the mild form. VWD occurs in men and women equally, but women are more likely to notice the symptoms of VWD due to heavy or abnormal bleeding during their menstrual periods and after childbirth. There are many gynecological and physical causes for heavy periods, such as endometriosis, thyroid problems and cancer; however, the cause is not identified in half the cases. A CDC-Emory University survey found that gynecologists rarely considered bleeding disorders as a cause of heavy menstrual bleeding. However, recent research from Europe and CDC has shown that 15–20% of women with heavy periods have inherited bleeding disorders. Women with VWD interviewed by CDC reported an average of 16 years between the onset of bleeding symptoms and diagnosis of a bleeding disorder. CDC and the National Hemophilia Foundation have been working to encourage gynecologists to consider bleeding disorders in women who have heavy menstrual bleeding, also called menorrhagia. As a result, the American College of Obstetricians and Gynecologists has recently recommended screening for VWD in these women. An important part of increasing the awareness among physicians and their patients with heavy periods who may have an underlying bleeding disorder is referral for appropriate diagnosis. Federally funded Hemophilia Treatment Centers (HTCs) are thought to be the best source for appropriate laboratory diagnosis, however, the following concerns have been raised: (1) Anecdotal reports from HTC providers describe reduced capacity of in-house laboratory support and access to specialty coagulation laboratory tests that are essential for appropriate diagnosis of bleeding disorders; (2) A CDC Public Health Practice Program Office (PHPPO) study demonstrated reduced capacity to perform specific coagulation tests through their survey of hospital laboratories; but it is impossible to know if HTCs have higher capacity than the hospitals studied; (3) HTCs report that changes in third party payer policies, especially health maintenance organizations, are dictating the source of laboratory testing requiring shipment of laboratory specimens to sites away from the hospital that reduce the quality of the sample and affect the reliability of the results. It is important to assess the HTCs and determine their capabilities and barriers to delivering comprehensive care to patients with bleeding disorders. The setting for the proposed study is the 135 federally funded HTCs, and the Directors and Lab Directors of these 135 HTCs will be the potential respondents. A survey will be distributed to the above personnel to ascertain their perceptions of lab capabilities and procedures. The data received from this survey will allow CDC to evaluate the functional status of HTC labs, describe the services available, and make programmatic decisions that will best serve the medical needs of this population. There will be no cost to the respondents other than their time. The total estimated annualized burden hours are 90. ESTIMATED ANNUALIZED BURDEN TABLE Type of respondents Number of respondents HTC Directors .............................................................................................................................. Lab Directors ............................................................................................................................... Dated: January 11, 2006. Betsey S. Dunaway, Acting Reports Clearance Officer, Centers for Disease Control and Prevention. [FR Doc. E6–617 Filed 1–19–06; 8:45 am] Centers for Disease Control and Prevention review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 639–4766 or send an email to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of Management and Budget, Washington, DC or by fax to (202) 395–6974. Written comments should be received within 30 days of this notice. [30Day–06–0213] Proposed Project BILLING CODE 4163–18–P wwhite on PROD1PC65 with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency Forms Undergoing Paperwork Reduction Act Review The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under VerDate Aug<31>2005 16:16 Jan 19, 2006 Jkt 208001 National Vital Statistics Report Forms—Extension—National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 135 135 Response per respondent Burden per response (in hours) 1 1 20/60 20/60 Background and Brief Description The National Vital Statistics Report Forms project (0920–0213) is an approved collection and compilation of national vital statistics. This collection dates back to the beginning of the 20th century and has been conducted since 1960 by the Division of Vital Statistics of the National Center for Health Statistics, CDC. The collection of the data is authorized by 42 U.S.C. 242k. The National Vital Statistics Report forms provide counts of monthly occurrences of births, deaths, infant deaths, marriages, and divorces. Similar data have been published since 1937 and are the sole source of these data at the national level. The data are used by the Department of Health and Human Services and by other government, E:\FR\FM\20JAN1.SGM 20JAN1

Agencies

[Federal Register Volume 71, Number 13 (Friday, January 20, 2006)]
[Notices]
[Pages 3305-3306]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-617]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-06-05AV]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 639-4766 or send an e-mail
to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of
Management and Budget, Washington, DC or by fax to (202) 395-6974.
Written comments should be received within 30 days of this notice.

Proposed Project

Hemophilia Treatment Center Laboratory Survey--New--National Center
on Birth Defects and Developmental Disabilities (NCBDDD), Centers for
Disease Control and Prevention (CDC).

[[Page 3306]]

Background and Brief Description

Up to 2 million women in the United States may have an inherited
bleeding disorder and not know it. Many women learn to live with the
problems their bleeding causes, such as heavy periods, and do not
realize that they may have a bleeding disorder. Other women may have
more serious bleeding problems such as hemorrhages after childbirth or
surgery, and some have hysterectomies to end their heavy periods. With
proper diagnosis, women with bleeding disorders could avoid these
complications and surgeries. Management of bleeding in these women can
decrease heavy periods and can improve quality of life.
The most common bleeding disorder is called Von Willebrand disease
(VWD). VWD is caused by a deficiency or defect in the body's ability to
make a protein, Von Willebrand factor, which helps blood clot. The
symptoms of VWD can range in severity; however, 90 percent of people
who have this disease have the mild form. VWD occurs in men and women
equally, but women are more likely to notice the symptoms of VWD due to
heavy or abnormal bleeding during their menstrual periods and after
childbirth. There are many gynecological and physical causes for heavy
periods, such as endometriosis, thyroid problems and cancer; however,
the cause is not identified in half the cases. A CDC-Emory University
survey found that gynecologists rarely considered bleeding disorders as
a cause of heavy menstrual bleeding. However, recent research from
Europe and CDC has shown that 15-20% of women with heavy periods have
inherited bleeding disorders. Women with VWD interviewed by CDC
reported an average of 16 years between the onset of bleeding symptoms
and diagnosis of a bleeding disorder. CDC and the National Hemophilia
Foundation have been working to encourage gynecologists to consider
bleeding disorders in women who have heavy menstrual bleeding, also
called menorrhagia. As a result, the American College of Obstetricians
and Gynecologists has recently recommended screening for VWD in these
women.
An important part of increasing the awareness among physicians and
their patients with heavy periods who may have an underlying bleeding
disorder is referral for appropriate diagnosis. Federally funded
Hemophilia Treatment Centers (HTCs) are thought to be the best source
for appropriate laboratory diagnosis, however, the following concerns
have been raised: (1) Anecdotal reports from HTC providers describe
reduced capacity of in-house laboratory support and access to specialty
coagulation laboratory tests that are essential for appropriate
diagnosis of bleeding disorders; (2) A CDC Public Health Practice
Program Office (PHPPO) study demonstrated reduced capacity to perform
specific coagulation tests through their survey of hospital
laboratories; but it is impossible to know if HTCs have higher capacity
than the hospitals studied; (3) HTCs report that changes in third party
payer policies, especially health maintenance organizations, are
dictating the source of laboratory testing requiring shipment of
laboratory specimens to sites away from the hospital that reduce the
quality of the sample and affect the reliability of the results. It is
important to assess the HTCs and determine their capabilities and
barriers to delivering comprehensive care to patients with bleeding
disorders.
The setting for the proposed study is the 135 federally funded
HTCs, and the Directors and Lab Directors of these 135 HTCs will be the
potential respondents. A survey will be distributed to the above
personnel to ascertain their perceptions of lab capabilities and
procedures.
The data received from this survey will allow CDC to evaluate the
functional status of HTC labs, describe the services available, and
make programmatic decisions that will best serve the medical needs of
this population.
There will be no cost to the respondents other than their time. The
total estimated annualized burden hours are 90.

Estimated Annualized Burden Table
----------------------------------------------------------------------------------------------------------------
Burden per
Type of respondents Number of Response per response (in
respondents respondent hours)
----------------------------------------------------------------------------------------------------------------
HTC Directors................................................... 135 1 20/60
Lab Directors................................................... 135 1 20/60
----------------------------------------------------------------------------------------------------------------

Dated: January 11, 2006.
Betsey S. Dunaway,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E6-617 Filed 1-19-06; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.